IMCR Immunocore Holdings plc

Nasdaq Biological Products, (No Diagnostic Substances) X0 CIK: 0001671927
AI RATING
HOLD
65% Confidence

Investment Thesis

Strong revenue growth (29% YoY) and EPS expansion (30.4% YoY) demonstrate market traction, but the stark disconnect between reported net income and negative operating cash flow (-$13.8M) raises critical questions about earnings quality and sustainability. Elevated leverage (1.11x D/E) combined with cash burn presents financial stability risks despite substantial liquid reserves.

Strengths

  • + Strong topline growth of 29% YoY with net margin expansion to 12.2%
  • + Diluted EPS growth of 30.4% demonstrates operating leverage and market momentum
  • + Robust liquidity position with $452.7M cash and 4.18x current ratio providing runway

Risks

  • ! Critical disconnect: negative operating cash flow of -$13.8M despite positive net income signals earnings quality concerns or unsustainable working capital dynamics
  • ! Elevated leverage with 1.11x debt-to-equity and 2.4x interest coverage leaves limited margin for error
  • ! Extremely low returns on equity (3.3%) and assets (1.2%) indicate inefficient capital deployment despite growth

Key Metrics to Watch

Financial Metrics

Revenue
106.7M
Net Income
13.0M
EPS (Diluted)
$0.25
Free Cash Flow
-15.6M
Total Assets
1.1B
Cash
452.7M

Profitability Ratios

Gross Margin N/A
Operating Margin 6.8%
Net Margin 12.2%
ROE 3.3%
ROA 1.2%
FCF Margin -14.6%

Balance Sheet & Liquidity

Current Ratio
4.18x
Quick Ratio
4.15x
Debt/Equity
1.11x
Debt/Assets
63.3%
Interest Coverage
2.39x
Long-term Debt
438.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-08T10:41:51.459585 | Data as of: 2026-03-31 | Powered by Claude AI